Compare MDXH & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | RPID |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.4M | 204.3M |
| IPO Year | 2021 | 2021 |
| Metric | MDXH | RPID |
|---|---|---|
| Price | $3.82 | $4.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $8.00 |
| AVG Volume (30 Days) | 151.4K | ★ 311.8K |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,069,000.00 | $30,523,000.00 |
| Revenue This Year | $23.34 | $19.36 |
| Revenue Next Year | $22.98 | $21.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.68 | 16.63 |
| 52 Week Low | $1.35 | $1.10 |
| 52 Week High | $5.33 | $4.88 |
| Indicator | MDXH | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 59.15 |
| Support Level | $3.56 | $2.92 |
| Resistance Level | $4.34 | $4.88 |
| Average True Range (ATR) | 0.27 | 0.38 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 61.19 | 61.22 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.